Akorn Pharmaceuticals is giving 340B covered entities refunds for overcharges on 24 NDCs from Q1 2019 through Q4 2021.

Akorn Providing Refunds for 340B Overcharges

Akorn Pharmaceuticals, a generic and brand drug manufacturer, is giving 340B covered entities refunds for overcharges on 24 NDCs from Jan. 1, 2019, through Dec. 31, 2021.

The U.S. Health Resources and Services Administration (HRSA) posted Akorn’s notice to entities on its website this week. A HRSA fiscal year 2021 audit found that Akorn “did not determine the difference between new drug price estimates and the actual 340B ceiling price and offer a refund.” HRSA also found that the company “did not submit quarterly pricing data to 340B OPAIS,” the 340B program database.

Akorn Pharmaceuticals, a generic and brand drug manufacturer, is giving 340B covered entities refunds for overcharges on 24 NDCs from Jan. 1, 2019, through Dec. 31, 2021.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report